Article
Clinical and genetic risk factors for the prediction of hepatotoxicity induced by a docetaxel, epirubicin and cyclophosphamide regimen in breast cancer patients.
Pharmacogenomics - 1 Jan 2021
Huang Shunmin, Yang Jing, Fu Fangmeng, Wang Chuan, Guo Xiaoxiong, He Baochang, Xiao Danni, Cai Hongfu, Liu Maobai
Abstract excerpt
Aim: To screen clinical and genetic risk factors and examine their combined effect on docetaxel, epirubicin and cyclophosphamide (TEC) regimen-induced liver injury (TEC-ILI). Patients & methods: We enrolled 396 breast cancer patients, and TEC-ILI-associated factors were screened by logistic regression analyses. Results:SOD2 rs4880 and ABCG2 rs2231142 polymorphisms correlated with an increased risk of TEC-ILI....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.